Risk Factors, Risk Reduction & Tobacco Control  This would include classic epidemiology, family history, gender differences, lung cancer in persons who have never smoked, exposure to radon, tobacco, and asbestos, cessation programs, chemoprevention, and efforts to reduce tobacco production, sales, and distribution.  

Tumor Biology – Preclinical Biology  This would include in vitro basic science studies and cell lines. 

Tumor Biology – Translational Biology  This would include patient derived cells, animal models, and drug development studies.  

Screening and Early Detection This would include low-dose computed tomography (LDCT) and radiology but also ongoing research into other methods and technologies to screen and detect thoracic cancers early.  

Pulmonology and Staging This would include endoscopic ultrasound (EUS), endobronchial ultrasound (EBUS), navigational bronchoscopy (NB), positron emission tomography (PET)-CT, mediastinoscopy, and staging system analyses.  

Early-Stage Non-small Cell Lung Cancer This would include clinically related studies on localized/early-stage NSCLC, surgery, radiation therapy, neoadjuvant and adjuvant therapies, and immunotherapy and targeted therapies in this setting. 

Pathology and Biomarkers This would include anatomic and molecular pathology, tissue and circulating biomarker studies, and clinical trial associated predictive biomarkers. 

Local-Regional Non-small Cell Lung Cancer This would include clinically related studies on local-regional/locally advanced NSCLC (Stage III), surgery, radiation therapy, neoadjuvant and adjuvant therapies, immunotherapy and targeted therapies in this setting, and new multi-modality approaches. 

Metastatic Non-small Cell Lung Cancer – Local Therapies This would include clinically relevant studies in metastatic/advanced NSCLC related to radiation therapy, surgery, and other ablative techniques.

Metastatic Non-small Cell Lung Cancer – Cytotoxic Therapy This would include clinically relevant studies in metastatic/advanced NSCLC related to targeted therapy, including chemotherapy and nonclassical chemotherapy agents (ie ADCs), radiation oncology, new agents, new combinations, and new sequencing of drugs.  

Metastatic Non-small Cell Lung Cancer – Immunotherapy This would include clinically relevant studies in metastatic/advanced NSCLC related to targeted therapy, including new agents, new combinations including radiation oncology, and new sequencing of drugs.  

Metastatic Non-small Cell Lung Cancer – Targeted Therapy This would include clinically relevant studies in metastatic/advanced NSCLC related to targeted therapy, including new agents, new combinations including radiation oncology, and new sequencing of drugs.  

Small Cell Lung Cancer and Neuroendocrine Tumors This would include clinically related studies on small cell lung cancer and neuroendocrine tumors. Strictly translational and basic science studies should go to tumor biology. 

Mesothelioma, Thymoma, and Other Thoracic Tumors This would include clinically related studies on mesothelioma, thymoma, thymic carcinoma, and other thoracic tumors. 

Multidisciplinary Care: Nursing, Allied Health and Palliative Care This would include nursing, allied health, palliative and supportive care, symptom management, decision-making, decision support techniques, ethics, quality of life, integrative care, rehabilitation, physiotherapy, and survivorship care. 

Patient Advocacy This would include patient advocacy, patient survivorship, community outreach, patient-driven research, advocacy and patient foundations and organizations, patient reported outcomes, and lung cancer stigma.  

Global Health, Health Services, and Health Economics This would include large real-world database studies across tumor types and stages, disparities identification and solutions, studies that examine the cost-effectiveness of therapies, diagnostics, or pathway implementation, programs that help improve the efficiency of health systems or patient management, and registry creation descriptions.